Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06823037 · ClinicalTrials.gov registry record · NA
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
A NA study of Contraception and Pharmaceutical Services, sponsored by EMPOWERX.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06823037: Recruiting NA study of Contraception and Pharmaceutical Services, sponsored by EMPOWERX.
NCT06823037 is a NA study of Contraception and Pharmaceutical Services that is actively recruiting participants, run by EMPOWERX. The registered enrollment target is 150 participants, below the 453-participant average among 72 other Contraception trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06823037, a NA study of Contraception and Pharmaceutical Services, is actively recruiting participants, sponsored by EMPOWERX.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if use of the HAPPI software can improve pharmacist-provided birth control services. The main questions it aims to answer are: 1. Does the HAPPI software make it easier for pharmacists to provide birth control services in their pharmacy? 2. Does the HAPPI software make it easier for patients to access birth control? Researchers will compare pharmacists' implementation and patients' access when using the HAPPI software and when not using the HAPPI software to see if the software improves implementation and access. Participants will include pharmacists and patients. Pharmacists will be asked to provide birth control services as normal while using the HAPPI software. Patients will be asked to receive birth control services from a pharmacist as normal, while using the HAPPI software.
Primary Outcome
Implementation outcomes will focus on how the service (pharmacist-prescribed contraceptive services) is implemented. Name of the Measurement: Implementation - Service Characteristics Measurement Tool: Pharmacy Service Characteristics Questionnaire Unit of Measure: * Number of pharmacists involved in providing birth control services
Conditions Studied
Interventions
- OTHER HAPPI software
Study Locations (1)
California
- EmpoweRx, Inc - Del Mar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-10-09 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT06823037 shows while recruiting
NCT06823037 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 453-participant average among 72 other Contraception trials with a reported enrollment target (67% lower).
The record links to 4 conditions, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which HAPPI software is the first listed.
NCT06823037 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06823037 about?
NCT06823037 is a clinical study titled "Hormonal Contraception Access Through Pharmacist Prescribing Implementation". The goal of this clinical trial is to learn if use of the HAPPI software can improve pharmacist-provided birth control services. The main questions it aims to answer are: 1. Does the HAPPI software make it easier for pharmacists to provide birth control services in their pharmacy? 2. Does the HAPPI...
What is the current status of trial NCT06823037?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-10-09. Estimated completion is 2026-08-31.
What conditions does trial NCT06823037 study?
This clinical trial studies the following conditions: Contraception, Pharmaceutical Services, Access and Linkage to Healthcare, Technology Use.
What interventions are being tested in trial NCT06823037?
The interventions under investigation include: HAPPI software (OTHER).
Who is sponsoring clinical trial NCT06823037?
This trial is sponsored by EMPOWERX, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06823037 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06823037's enrollment target sits among peer trials
150 37th of 72 higher than 36 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
-
Contraceptive Efficacy Study of Ovaprene
RECRUITING · NA
-
Intervening on Women's Health for Rural Young Cancer Survivors
RECRUITING · NA
-
Patient-centered Information on Permanent Contraception
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI